AngioDynamics Inc. (NASDAQ:ANGO)
Faster Growth in the Higher-Margin Business Could Improve Earnings Quality
AngioDynamics, Inc. (NASDAQ: ANGO) reported fiscal first-quarter 2027 revenue of $80.9 million, up 6.9%, in its October 8 presentation. Med Tech revenue increased 13.2% to $39.9 million, compared with 1.4% growth in Med Device revenue. The presentation reported segment gross margins of 66.2% and 52.7%, respectively.
That combination supports a bullish product-mix thesis. The faster-growing segment also carries the higher gross margin, meaning continued expansion could improve the economics of each sales dollar. The opportunity therefore extends beyond increasing revenue: a larger contribution from Med Tech could help absorb operating costs and strengthen profitability.
Cash generation remains the decisive test. The company used approximately $15.3 million in operating cash during the quarter, despite reporting $5 million in adjusted EBITDA. Management expects positive operating cash flow for fiscal 2027, but that remains an outlook rather than an achieved result. Investors should watch whether subsequent quarters narrow the gap between adjusted operating performance and cash generation. Sustained Med Tech growth accompanied by improving cash flow would provide stronger support for the bullish case.
YOU MUST READ THIS: Top 10 Healthcare Stocks Under $10 to Watch Now
Disclosure: No material interests to disclose. This article was originally published on BioTech HealthX.
